scout

All News

LOS ANGELES--Use of a radiolabeled monoclonal antibody in patients with relapsed B-cell lymphoma may allow higher doses of radiation to the tumor and less toxicity to normal organs, Oliver W. Press, MD, PhD, of the University of Washington Medical Center, Seattle, said in his ASCO presentation.

STANFORD, Calif--Researchers at Stanford University Medical Center have found profound shortages of naïve T cells among individuals infected with HIV. In contrast, previous studies have suggested that naïve T cells remain stable with the progression of HIV disease.

TORONTO, Canada--The benefits of annual mammography screening for women aged 50 and over are undisputed, but experts are still polarized over whether the screening procedure is worthwhile for women aged 40 to 49.

NEW YORK--Depression is more common in patients with advanced cancer and can have an adverse effect on cancer pain. For example, in patients with advanced breast cancers, a study showed that concomitant depression and interpretation of pain influenced pain more than site of disease or presence of metastases, Memorial Sloan-Kettering psychiatrist William S. Breitbart, MD, said at a conference sponsored by Cancer Care, Inc., a social work agency for cancer patients and their families.

WASHINGTON--Probably the best-informed group of American consumers of health care are the 9 million federal employees enrolled in the government's health-care plan, Representative Patricia Schroeder (D-CO) said at the Association of Community Cancer Centers (ACCC) annual meeting.

ROCKVILLE, Md--Diane Van Ostenberg, BS, RN, has assumed the office of president of the Association of Community Cancer Centers (ACCC), a national organization of 478 hospital cancer programs.

NEW YORK--In its aggressive attacks on the American Medical Association and American Academy of Dermatology, the tanning industry uses disinformation to obscure the fact that artificial sources of ultraviolet (UV) light are no safer than the sun, said Rex Amonette, MD, president of the American Academy of Dermatology and clinical professor of dermatology at the University of Memphis.

GAITHERSBURG, Md--The National Institutes of Health (NIH) has licensed its broad patent covering gene therapy techniques to Genetic Therapy, Inc. The inventors cited on the patent are gene therapy pioneers W. French Anderson, Steven Rosenberg, and Michael Blaese.

NEW ORLEANS--Diphtheria toxin-based "fusion toxins" can produce durable remissions in malignancies that express the targeted receptor, and they are safe and well-tolerated, said John R. Murphy, PhD, chief of biomolecular medicine, Boston University Medical Center Hospital.

TORONTO, Canada--For years, scientists have known that defective genes allow tumors to grow. Today, researchers blame as many as 30% of all cancers on just one of those genes, the ras gene, the first oncogene discovered in human cancers. Animal research presented at the meeting of the American Association for Cancer Research (AACR) may someday lead to cancer drugs that can block the effects of this oncogene in humans.

BOULDER, Colo--NeXagen, Inc. and Vestar, Inc. have merged to form NeXstar Pharmaceuticals, Inc. One focus of the new company will be the liposomal delivery of oligonucleotides. The company's initial product, AmBisome, is a liposomal formulation of amphotericin B, which has been approved for marketing in 16 countries for the treatment of life-threatening systemic fungal infections that fail to respond to conventional amphotericin B therapy.

NEW ORLEANS--Researchers at the Dana-Farber Cancer Institute have initiated a trial of an angiogenesis inhibitor in children with recurrent solid tumors, the idea being to stunt the growth of new blood vessels that nourish the tumor. Speaking at the American Cancer Society Science Writers Seminar, Dr. Stephen Skapek, of the Department of Pediatrics, Harvard, said that an agent known as TNP-470 (formerly AGM-1470) was found to be a "potent" inhibitor of blood vessel growth in immunosuppressed mice and produced a desirable adverse effects profile.

COLUMBUS, Ohio--Research from Ohio State University points to phosphoramide mustard as the cyclophosphamide metabolite with the greatest alkylating activity, and suggests that a reformulation of the chemotherapeutic agent to deliver only this metabolite could reduce toxicity without decreasing anticancer activity.

FORT LAUDERDALE, Fla-Worksite cancer screening programs are designed to help reduce cancer morbidity and mortality among employees, but have the added benefit of enhancing the employer's corporate image and boosting employee morale.

WASHINGTON--The House Budget Committee proposed a plan that calls for a 5% reduction in funding for NIH in fiscal 1996, which amounts to about $1 billion out of a total NIH budget of $11.8 billion.

NEW YORK--Fatigue is too often a part of life for cancer patients and can erode their quality of life. "We need to talk to cancer patients about their energy level and ability to cope, and educate them about how to deal with the treatment and the disease itself," said Lois Almadrones, RN, MPA, OCN, clinical research associate, Memorial Sloan-Kettering Cancer Center.

RICHMOND, BC, Canada--Xillix Technologies Corp. has closed the North American multicenter clinical trial of its LIFE (lung imaging fluorescence endoscope)-Lung Imaging System that began in April, 1993.

NEW YORK--About 30% of the cancer patients he is asked to evaluate for depression turn out to have delirium, said Memorial Sloan-Kettering psychiatrist William S. Breitbart, MD, at a conference sponsored by Cancer Care, Inc.

n NEW YORK--Roughly 70% of cancer patients complain of fatigue at some point in their illness, and a search for reversible causes and multiple etiologies of such fatigue should be a part of standard practice, Ronald Blum, MD, said at a a symposium on fatigue in cancer sponsored by Cancer Care, Inc.

WASHINGTON--The Physician Payment Review Commission (PPRC) released a study describing how managed care plans select and pay physicians in their networks. The study, conducted by Mathematica Policy Research and the Medical College of Virginia, is the first systematic attempt to compare forms of managed care.

HOUSTON--Passage of the Contract with America legislation, as currently written, could hinder tobacco control efforts for years to come, a Washington, DC, attorney said at the American Society for Preventive Oncology (ASPO) meeting.

BOSTON--During its 48th Cancer Symposium, the Society of Surgical Oncology (SSO) presented Richard A. Bloch, founder of H&R Block, with its James Ewing Layman's Award, given annually to a nonphysician. The award honors Mr. Bloch for his contribution to improving the care of cancer patients.

CHICAGO--A ruling by the US Court of Appeals for the Seventh Circuit may put a damper on the class action suit filed in a federal court in Louisiana against tobacco manufacturers.